| Mallory G Berberich, DPT | |
|
801 Auburn Way N Ste E, Auburn, WA 98002-4164 | |
| (253) 736-2340 | |
| (253) 736-2343 |
| Full Name | Mallory G Berberich |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 11 Years |
| Location | 801 Auburn Way N Ste E, Auburn, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174077663 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | PT291643 (California) | Secondary |
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Therapy Management Services Pllc | 0143500983 | 94 |
News Archive
Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases.
Heart attack patients who take part in a lifestyle improvement programme feel better - especially when they do additional physical activity. That's the finding of a large study presented today on ACVC Essentials 4 You, a scientific platform of the European Society of Cardiology.
Twenty-five percent of inflammatory bowel disease (IBD) patients are diagnosed as children or adolescents - at the peak of their social and educational development.
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received marketing approval in Europe for Kisqali (ribociclib) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.
Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke.
› Verified 7 days ago
| Entity Name | Therapy Management Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1710330378 PECOS PAC ID: 0143500983 Enrollment ID: O20161213001176 |
News Archive
Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases.
Heart attack patients who take part in a lifestyle improvement programme feel better - especially when they do additional physical activity. That's the finding of a large study presented today on ACVC Essentials 4 You, a scientific platform of the European Society of Cardiology.
Twenty-five percent of inflammatory bowel disease (IBD) patients are diagnosed as children or adolescents - at the peak of their social and educational development.
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received marketing approval in Europe for Kisqali (ribociclib) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.
Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mallory G Berberich, DPT 11711 Ne 12th St, Ste 3a, Bellevue, WA 98005-2461 Ph: (916) 858-0950 | Mallory G Berberich, DPT 801 Auburn Way N Ste E, Auburn, WA 98002-4164 Ph: (253) 736-2340 |
News Archive
Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases.
Heart attack patients who take part in a lifestyle improvement programme feel better - especially when they do additional physical activity. That's the finding of a large study presented today on ACVC Essentials 4 You, a scientific platform of the European Society of Cardiology.
Twenty-five percent of inflammatory bowel disease (IBD) patients are diagnosed as children or adolescents - at the peak of their social and educational development.
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received marketing approval in Europe for Kisqali (ribociclib) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.
Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke.
› Verified 7 days ago